Hat mitgewirkt an:
-
Radioligandentherapie mit ¹⁷⁷Lutetium-PSMA-617 in chemorefraktären Patienten mit einem im jungen Alter erstdiagnostizierten Prostatakarzinom im metastasierten, kastrationsresistenten Stadium
-
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
-
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
-
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement